Recent Headlines
Polar Lab Projects Redefines Laboratory Relocation Standards with Global, Single-Source Logistics Solution
Polar Lab Projects is setting a new standard in laboratory relocations and logistics, offering a single-source, seamless solution tailored to the life sciences industry worldwide. With an extensive network of industry experts, they provide unmatched service excellence, meeting clients' needs wherever they operate. - November 06, 2024 - Polar Lab Projects LLC
Parvus Announces First Human Subject Dosed in a Clinical Trial with PVT201, a First-in-Class Off-the-Shelf Regulatory T-cell (Treg) Inducing pMHC Nanomedicine Therapy
Parvus Therapeutics, a private clinical-stage biopharmaceutical company developing a pipeline of novel treatments for autoimmune disease announced the successful dosing of the first subject in a Phase 1/2, first-in-human study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of PVT201 single ascending doses in healthy subjects and primary biliary cholangitis patients. - October 17, 2024 - Parvus Therapeutics U.S., Inc.
Microvascular Therapeutics Announce Completion of Phase 2 Study Enrollment for MVT-100
Microvascular Therapeutics (MVT), a pioneering healthcare research and development company, is pleased to announce the completion of enrollment in MVT’s Phase 2 program using its microbubble product, MVT-100, for endocardial border delineation. This study, An Ascending Dose Comparison of... - September 13, 2024 - Microvascular Therapeutics, Inc.
Parvus Therapeutics Announces Leadership Appointments to Support Development from Preclinical Into Clinical
New Positions Enhance Parvus Capability to Execute the Translation of Multiple Drug Candidates into the Clinic. - August 06, 2024 - Parvus Therapeutics U.S., Inc.
Parvus Therapeutics Has Received Orphan Drug Designation for Primary Biliary Cholangitis and Human Research Ethics Committee Approval to Begin Clinical Testing
Parvus Therapeutics announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to PVT201 for the treatment of Primary Biliary Cholangitis (PBC) and PVT201 has obtained Australian Human Research Ethics Committee (HREC) approval to initiate a first-in-human... - July 29, 2024 - Parvus Therapeutics U.S., Inc.
Cayman Chemical Expands Molecular Diagnostic Research Offerings Through Partnership with PCRassays.com
Cayman Chemical, a leading supplier of research tools for the life science community, has widened their portfolio to include molecular-based detection kits through a strategic partnership with PCRassays.com. PCRassays.com offers more than 200 qPCR-based assays for infectious diseases, over 50 of... - June 07, 2024 - Cayman Chemical Company
Mirror Biologics, Inc. Appoints Elizabeth Czerepak as Chief Financial Officer and VP Corporate Development
Mirror Biologics, Inc., a clinical stage biopharmaceutical company announces the appointment of Elizabeth Adkins Czerepak as Chief Financial Officer (CFO) and Vice President of Corporate Development effective April 15, 2024. Ms. Czerepak has served as CFO of several biotechnology companies over... - April 18, 2024 - Mirror Biologics, Inc.
Parvus Announces Collaboration with AbbVie to Develop IBD Therapies Based on the Parvus Navacim Platform Technology
The collaboration will combine AbbVie’s expertise in Immunology with Parvus’ innovative Navacim™ regulatory T cells (Treg) immune tolerization platform technology to develop therapies for Inflammatory Bowel Disease Parvus Therapeutics announced today that it has entered into an... - March 20, 2024 - Parvus Therapeutics U.S., Inc.
ACL Digital and PhoenixAI.tech Partner to Take AI-Driven Drone Technology to New Heights
The strategic partnership enhances ACL Digital’s capabilities with PhoenixAI.tech, focusing on AI drone solutions for UAVs, IoT, and edge computing to revolutionize operations significantly Beyond Visual Line of Sight (BVLOS) missions. - March 16, 2024 - ACL Digital
Defined Bioscience Introduces Ready-CEPT™: A New Cell Viability Enhancer
Defined Bioscience is pleased to announce the launch of Ready-CEPT™ 1000X, a new product designed to improve stem cell survival, growth, and health during critical processes such as routine passaging, cryopreservation, and freeze-thaw recovery. - March 11, 2024 - Defined Bioscience Inc.
Cayman Chemical Introduces LipidLaunch™, Expands Portfolio of Lipid Nanoparticle Research Tools to Support Advances in RNA Therapies
Cayman Chemical introduces the latest addition to the company’s portfolio of lipid nanoparticle (LNP) research tools for academic, pharma, and biotech researchers worldwide. The LipidLaunch™ product line helps researchers pursue LNPs for the delivery of nucleic acid therapies in untold health applications, ranging from vaccine development to cancer and cell or gene therapies. - February 22, 2024 - Cayman Chemical Company
Biopharmaceutical Sponsor Interaction with Clinical Site Networks Pulse Report
Sponsor Outsourcing Dollars May Shift to Clinical Site Networks, Transforming the CRO Relationship - February 13, 2024 - Life Science Strategy Group, LLC
Microvascular Therapeutics Welcomes Thom Tulip as Chief Business Officer
Microvascular Therapeutics Inc. (MVT), a clinical-stage biotech company at the forefront of developing the next generation of microbubbles unlocking the therapeutic potential of ultrasound, proudly announces the appointment of Dr Thom Tulip as their new Chief Business Officer. In this pivotal role, Dr Tulip will lead capital raises to propel MVT's cutting-edge technologies into the market. - February 10, 2024 - Microvascular Therapeutics, Inc.
Flow Circuits and Rapid Fluidics Ltd. Announce Partnership to Drive Microfluidic Innovation
Flow Circuits design platform and Rapid Fluidics 3D Print capabilities perfectly complement each other for rapid fluidic system development. Combined they empower researchers in diverse markets such as Pharmaceutical & Life Sciences Research, Point of Care Testing and Clinical Diagnostics, and Environment and Industrial Analytics. - February 05, 2024 - Rapid Fluidics Ltd
Patient Experience and Satisfaction with Electronic Consent, Onboarding, and Diaries in Clinical Trials Report
New Market Research Shows Different Patient Preferences for Electronic Diaries - January 31, 2024 - Life Science Strategy Group, LLC
Impact of the In Vitro Diagnostic Regulation on Clinical Trials in the EU and CRO Outsourcing Report
IVDR Delays Driving Trial Sponsors to Actively Seek Alternative Site and CRO Outsourcing Strategies - January 17, 2024 - Life Science Strategy Group, LLC
Breakthrough Study by Microvascular Therapeutics Reveals Fibrin-Targeted Phase Shift Microbubbles as Promising Solution for Microvascular Obstruction
Microvascular Therapeutics, a trailblazing healthcare research and development company, announces a groundbreaking study on the treatment of Microvascular Obstruction (MVO) through sonoreperfusion. The study, led by Dr. John J. Pacella and his team at the Center for Ultrasound Molecular Imaging and... - December 13, 2023 - Microvascular Therapeutics, Inc.
Microvascular Therapeutics Selected as a Participant in the 2023 H7 BioCapital Accelerator Program
Microvascular Therapeutics (MVT), a clinical stage biopharma pioneering the potential of ultrasound in diagnostics and theranostics, has been selected to join the prestigious H7 Healthcare Accelerator 2023 Cohort, powered by H7 BioCapital. The program is renowned for providing a dynamic platform... - December 13, 2023 - Microvascular Therapeutics, Inc.
Microvascular Therapeutics Receives $3.98M Award from Department of Defense for Its Cardiovascular Product
Microvascular Therapeutics (MVT), a clinical stage biotechnology company based in Tucson, AZ, was recently awarded a $3.98M FY22 Technology/Therapeutic Development – Funding Level 2 grant from the Congressionally Directed Medical Research Programs (CDMRP). Emmanuelle Meuillet, Chief... - October 18, 2023 - Microvascular Therapeutics, Inc.
Cayman Chemical Introduces a New Tool to Study Protein-Lipid Interactions
Cayman LipiDOT Strips™ are a simple tool for the rapid identification of protein-lipid interactions. Researchers can screen a protein of interest against 22 biologically relevant lipids in one assay in a single day at a lower price compared with existing commercial options. - October 04, 2023 - Cayman Chemical Company
Cayman and Navinci Announce Strategic Partnership, Expanding Access to Next-Generation Tools for Spatial Proteomics
Cayman and Navinci have partnered to bring next-generation proximity ligation-based solutions for spatial proteomics to US and Canada-based researchers. - July 13, 2023 - Cayman Chemical Company
PharmStars Announces Spring 2023 Accelerator Graduates: 13 Digital Health Startups Complete PharmStars’ Pharma-Focused Accelerator Program
PharmStars, the pharma-focused accelerator for digital health startups, announces that 13 startups have graduated from its Spring 2023 program focused on “Innovations in Women’s Health or Health Equity.” The graduating startups successfully completed PharmaU, PharmStars’ 10-week program. PharmaU culminated with a Showcase Event, held in Boston in May, that brought together the participating startups and PharmStars’ innovation-minded pharma members. - June 20, 2023 - PharmStars
PharmStars Announces “Digital Innovations in Therapeutic Delivery: Supply Chain to the Patient Interface” Theme for its Fall 2023 Accelerator
PharmStars, the pharma-focused accelerator for digital health startups, is accepting applications for its Fall 2023 cohort around the theme “Digital Innovations in Therapeutic Delivery: Supply Chain to the Patient Interface.” The cohort is open to startups with digital health solutions that pharma can use to innovate therapeutic supply chain management, medication delivery, or the patient-drug experience for small molecules, biologics, or advanced therapies. Applications are due July 10, 2023. - June 06, 2023 - PharmStars
New Research Benchmarks Biopharmaceutical Perceptions of Global CRO Thought Leadership
Landmark Research Analyzes Perspectives of US and EU Biopharma C-Suite, Clinical Operations and Medical/Regulatory Affairs Professionals on Global CRO Thought Leadership. - June 01, 2023 - Life Science Strategy Group, LLC
PharmStars Announces Spring 2023 Startup Showcase Event Underway
PharmStars, the pharma-focused accelerator for digital health startups, announces that its fourth Showcase Event begins May 16, 2023. The Showcase is the culmination of the Spring 2023 10-week accelerator program. At the Showcase, each startup in the fourth cohort makes a formal presentation to and meets individually with PharmStars’ pharma members. The theme of the Spring 2023 program is digital innovations in women’s health or health equity. - May 16, 2023 - PharmStars
Parvus Therapeutics Announces a Publication Describing the Cellular Origin of Treg Cells Generated Endogenously by Navacim Therapy
Parvus Therapeutics announced today the publication of data showing that peptide-MHC class II-coated nanoparticles (Navacims) operate by triggering the expansion of cognate T follicular helper (TFH) cells. - May 09, 2023 - Parvus Therapeutics U.S., Inc.
New Traceable Opioid Material® Kit Expands Coverage to Other Emerging Drugs of Concern in Seized Samples and Toxicological Casework
Cayman Chemical and the Centers for Disease Control and Prevention (CDC) have released a new addition to the Traceable Opioid Material® Kits (TOM Kits®) product line that expands testing laboratory capabilities beyond synthetic opioids to include additional emerging drugs of abuse that are commonly found as co-drugs in fentanyl-containing samples. - April 30, 2023 - Cayman Chemical Company
Liberum Independent Medical Education Announces Management Buyout
Liberum Independent Medical Education, provider of independent medical education (IME) to healthcare professionals worldwide, has announced a management buyout (MBO) from its original owner, OHC London Holdings Ltd. The MBO was led by the company's Managing Director, Celeste Kolanko who has taken ownership of the company which now operates as Liberum IME BV, and Liberum Independent Medical Education Ltd. - April 29, 2023 - Liberum Independent Medical Education Ltd
New Research on Decentralized Clinical Trial (DCT) Strategies to Boost Patient Diversity
Current and Future Clinical Trial Participants Link Enhanced Diversity and Inclusion of Underrepresented Patient Populations to DCT - March 29, 2023 - Life Science Strategy Group, LLC
Gallant Deepens Its Bench by Adding Dr. Valentine Williams as Senior Vice President of Clinical Development and Regulatory
Furthering its mission to bring regenerative medicine to all pets, animal biotech company Gallant Therapeutics welcomes an industry leader, Dr. Val Williams, to its pioneering team. - March 17, 2023 - Gallant
New Research Identifies Latest Clinical Development and CRO Outsourcing Trends in China
Groundbreaking Research Explores the Chinese Innovative Biopharmaceutical Clinical Development Market, CRO Outsourcing and Future Growth with Over 100 Chinese Biopharma Professionals - March 15, 2023 - Life Science Strategy Group, LLC
PharmStars Announces Fall 2022 Accelerator Graduates: 11 Digital Health Startups Complete PharmStars’ Pharma-Focused Accelerator Program
PharmStars, the pharma-focused accelerator for digital health startups, announces the graduation of 11 startups from its Fall 2022 program focused on “Innovations in Real-World Evidence.” The graduating startups successfully completed PharmaU, PharmStars’ 10-week education, and mentoring program. PharmaU culminated with a Showcase Event--held in Boston in early November--that brought together the participating startups and PharmStars’ seven innovation-minded pharma members. - December 08, 2022 - PharmStars
PharmStars Announces “Innovations in Women’s Health and Health Equity” Theme for Spring 2023 Accelerator
PharmStars, the pharma-focused accelerator for digital health startups, is now accepting applications for its Spring 2023 cohort with the theme “Digital Innovations in Women’s Health and Health Equity.” Startups with digital innovations that promote more equitable, inclusive healthcare for underserved population or focused on women’s health (e.g., breast, ovarian, and cervical cancer; gynecological conditions; osteoporosis; menopausal, hormonal, and reproductive conditions) are welcome to apply. - December 05, 2022 - PharmStars
Marty Rosenberg joins the Board of Scientific Advisors at Microvascular Therapeutics.
Microvascular Therapeutics (MVT), a clinical stage biotechnology company based in Tucson, Arizona, announced the appointment of Marty Rosenberg to the MVT Board of Scientific Advisors. Mr. Rosenberg brings a broad experience with the clinical development and global regulatory approval process for... - November 25, 2022 - Microvascular Therapeutics, Inc.
David Lim Joins the Team at Microvascular Therapeutics as Director of Finance
Microvascular Therapeutics (MVT), a clinical stage biotechnology company based in Tucson, Arizona, announced the appointment of David Lim as Director of Finance at MVT. Mr. Lim brings a broad experience with the business development and strategic financing for diagnostic pharmaceuticals across all... - November 25, 2022 - Microvascular Therapeutics, Inc.
Immunodominant Announces Call for Initial Investment Round as Company Prepares for Phase 2 Study of Oral OTC COVID-19 Drug
Immunodominant Inc., a drug discovery and development company engaged in progressing innovative research from academia to commercialization, today announced its intention to begin an initial financing round of up to $30 million. Immunodominant also announced today that it is scheduling a Phase 2 clinical study after a pre-IND meeting with the FDA for LACTOVID, a novel, oral, over-the-counter drug for the prevention and treatment of COVID-19. - November 20, 2022 - Immunodominant
Microvascular Therapeutics Receives Funds from the National Cancer Institute (NCI) for Its Brain Tumor Program
Microvascular Therapeutics (MVT), a clinical stage biotechnology company based in Tucson, AZ, was recently awarded a Phase I Small Business Innovation Research grant from the National Cancer Institute (NCI). Emmanuelle Meuillet, Chief Scientific and Operating Officer at MVT said, “We are... - November 18, 2022 - Microvascular Therapeutics, Inc.
PharmStars Announces Fall 2022 Startup Showcase Event
PharmStars, the pharma-focused accelerator for digital health startups, announces that its Fall 2022 Showcase Event will begin on November 8, 2022. The Showcase is the culmination of a 10-week startup accelerator program. At the Showcase Event, startups will make formal presentations to and meet... - November 08, 2022 - PharmStars
Biomed Industries, Inc. (“Biomed”) Today Announced the Closing of Its Merger with MedAware Systems, Inc., (“MedAware”)
Biomed Industries, Inc. (“Biomed”) today announced the closing of its merger with MedAware Systems, Inc., (“MedAware”), in which all issued and outstanding common shares of capital stock of MedAware will be exchanged for common stock of Biomed at a ratio of 5.33 shares of MedAware for 1 new common share of Biomed. The transaction valued at an aggregate of $20 million, to be paid by 2,259,170 common shares of Biomed. At present, Biomed has approximately 76,354,075 common shares issued. - November 07, 2022 - Biomed Industries, Inc.
Gallant Announces Hiring of John Klacking, Ph.D. as Chief Business Officer
Furthering its regenerative medicine therapeutics research and development, animal biotech company Gallant welcomes a pioneer in the biotech space. - October 25, 2022 - Gallant
Mirror Biologics, Inc. Announces Additional $20 Million Investment to Close Out $30 Million Series A Investment Round
Mirror Biologics, Inc., a clinical stage biopharmaceutical company today announced the completion of the final $20 million tranche of its $30 million Series A investment round with Bradbury Asset Management (Hong Kong), Limited. Bradbury provided an initial $10 million tranche for this round in... - October 11, 2022 - Mirror Biologics, Inc.
New Decentralized Clinical Trial (DCT) Patient Satisfaction and Participation Report
800 Current and Future Clinical Trial Participants Link Satisfaction and Willingness to Participate with Decentralized Strategies - September 21, 2022 - Life Science Strategy Group, LLC
Biomed Industries, Inc. to Acquire MedAware Systems, Inc. to Expand Its Artificial Intelligence Research for Drug Discovery in Alzheimer’s Disease
Biomed Industries, Inc. (“BIOMED” or the “Company”), has entered into a share exchange agreement to acquire all of the issued and outstanding shares of MedAware Systems, Inc. MedAware shares was valued at $1.50 per share and BIOMED’s share was valued at $8.00 per share. The transaction was valued at an aggregate of $18 million, to be paid in the form of 2,259,170 common shares of BIOMED. On the date of the Agreement, BIOMED has approximately 76,354,075 common shares. - September 21, 2022 - Biomed Industries, Inc.
CABRI Announces Call for Proposals on Specialized Pro-Resolving Mediator Analytical Methods
The Cayman Biomedical Research Institute (CABRI) is offering research grants in amounts up to $100,000 to support essential research on specialized pro-resolving mediator (SPM) analytical methods. - August 26, 2022 - Cayman Chemical Company
Deadline Extended: CABRI Announces Undergraduate Fellowships and Scholarship Program
The Cayman Biomedical Research Institute (CABRI) is accepting applications from undergraduate students who have been offered an unpaid laboratory research position under an accredited principal investigator. Applications will be accepted from August 22 until September 18, 2022. - August 26, 2022 - Cayman Chemical Company
Peptineo, LLC Selected by EPA to Provide EPA Nationwide Coverage for Point of Care (POC) COVID-19 Testing
The Environmental Protection Agency (EPA), Cincinnati Acquisition Division (CAD), has awarded Peptineo LLC, an emerging aerospace, health services, and defense solutions company, a three-year Blanket Purchase Agreement (BPA) to support a comprehensive COVID-19 testing program in support of the... - August 07, 2022 - Peptineo
PharmStars Announces Spring 2022 Accelerator Graduates: 11 Digital Health Startups Have Successfully Completed PharmStars’ Pharma-Focused Accelerator Program
PharmStars, the pharma-focused accelerator for digital health startups, announces the graduation of 11 startups from its Spring 2022 program. The graduates successfully completed the 10-week PharmaU program, which culminated with the Showcase Event held June 8-10 in Boston. The Showcase Event brought together the participating startups and PharmStars’ seven innovation-minded pharma members. - July 12, 2022 - PharmStars
PharmStars Announces “Innovations in Real-World Evidence” Theme for Fall 2022 Accelerator
PharmStars, the pharma-focused accelerator for digital health startups, announces it is now accepting applications for its Fall 2022 cohort with the theme, “Innovations in Real-World Evidence.” - June 15, 2022 - PharmStars
Defined Bioscience Announces Formation of Scientific Advisory Board
Defined Bioscience, a life science tools company pioneering the development of next generation ingredients for cell culture, today announced the formation of its scientific advisory board (SAB). The SAB is comprised of a distinguished group of academic and industry experts who will advise the... - June 15, 2022 - Defined Bioscience Inc.
PharmStars Announces Showcase Pitch Event for Spring 2022 Cohort
PharmStars, the pharma-focused accelerator for digital health startups, announces the start of its Showcase Event on June 8, 2022. The digital health startups that participated in the 10-week accelerator program will make formal presentations to, and answer questions from, the pharma members of PharmStars. All of PharmStars’ seven members are participating in the Showcase Event. - June 08, 2022 - PharmStars